Key facts
- This page summarizes Deborah Dunsire's Form 4 filing for Syros Pharmaceuticals, Inc. (SYRS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Jun 2024, 16:42.
Deborah Dunsire - 01 Jun 2024 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)
- Reporting relationship
- Director
- Issuer ticker
- SYRS
- Reported as of
- 01 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Jun 2024, 16:42:09 UTC
- Prior SEC filing
- 09 Jun 2023
- Next SEC filing
- 04 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Todd Rosenthal, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Deborah Dunsire filed Form 4 for Syros Pharmaceuticals, Inc. (SYRS) on 04 Jun 2024.
Change
- Previous filing in this sequence was filed on 09 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SYRS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +4,000
- Change %
- +50%
- Price
- Shares after
- 12,000
- Date
- 01 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SYRS
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -4,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,000
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents shares of common stock received upon vesting of a restricted stock unit ("RSU") award.
Footnote F2
Each RSU represents the contingent right to receive one share of the issuer's common stock.
Footnote F3
These RSUs vested in their entirety on the first anniversary of the date of grant of the award.